Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03288636 |
Recruitment Status :
Completed
First Posted : September 20, 2017
Last Update Posted : January 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HCV | Drug: Danoprevir Drug: Ritonavir Drug: Ravidasvir Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Study to Assess the Pharmacokinetics and Safety of Single Dose of Ravidasvir and Danoprevir/r and Repeated Doses of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers. |
Actual Study Start Date : | August 8, 2017 |
Actual Primary Completion Date : | September 14, 2017 |
Actual Study Completion Date : | October 28, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Experimental
PKGroup: Ravidasvir + Danoprevir/ Ritonavir |
Drug: Danoprevir
Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23 Drug: Ritonavir Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23 Drug: Ravidasvir Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Other Name: ASC16(RDV) |
Placebo Comparator: Placebo
Placebo Group: Placebo |
Drug: Placebo
Placebo |
- Incidence of adverse events [ Time Frame: 40 days ]Incidence of adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age between 18-45 years old;
- Male body weight not less than 50kg; Female body weight not less than 45kg; BMI in the range of 19~28kg/m2
- Healthy men or women based on history, physical examination, laboratory examination and ECG.
- Female subjects should be surgically sterilized (bilateral tubal ligation, bilateral ovariectomy or hysterectomy); or are willing to use at least one of the following contraceptive methods within 30 days of the first administration of the study drug until the last administration: I Male partner vas deferens ligation; II. Non-hormonal contraceptive methods: intrauterine contraceptives, condoms, contraceptive sponges, septa, vaginal ring containing sizing gel or cream.
- Male subjects should be surgically sterilized; or are willing to use at least one of the following contraceptive methods within 30 days from the first administration of the study to the last administration: I. Female partners abstinence during the study period (including no donation): II. Compounds use hormonal contraceptives (oral, vaginal, parenteral or transdermal); III. Subjects and / or their female partners use non-hormonal contraceptive methods: condoms, contraceptive sponges, membranes, intrauterine devices, Fine gel or cream of the vaginal ring.
- If female, the pregnancy test result should be negative during the screening period.
- Voluntary to sign the informed consent.
Exclusion Criteria:
- History or presence of cardiovascular disease, respiratory disease, endocrine and metabolic system disease, urinary system, digestive system, hematological system diseases, nervous system or Psychiatric diseases, and acute or chronic infectious disease and malignant tumor.
- A history of drug or food allergy.
- Positive test in any of the HBsAg、HCV Ab、HIV Ab and Syphilis Ab.
- Any of the AST、ALT、ALP、TBIL and DBIL exceed the upper limits of normal, or other laboratory test results exceeding the normal range and judged by the investigator to be clinically significant.
- History of gastrointestinal surgery, trunk vagotomy, intestinal excision or any other surgeries that could disturb gastrointestinal motility and PH absorption.
- Female who were during pregnancy, breastfeeding, period and unwilling to take reliable birth control method.
- Female partners were fertile and unwilling to take reliable contraceptive measures.
- Others as specified in the detailed protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03288636
China, Zhejiang | |
The first hospital of Zhejiang province | |
Hangzhou, Zhejiang, China, 310003 |
Responsible Party: | Ascletis Pharmaceuticals Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03288636 |
Other Study ID Numbers: |
ASC-ASC16-I-CTP-02 |
First Posted: | September 20, 2017 Key Record Dates |
Last Update Posted: | January 17, 2018 |
Last Verified: | October 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ritonavir HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |